Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the ef...

全面介紹

書目詳細資料

Principais autores:	Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti
格式:	Artigo
語言:	Inglês
出版:	PAGEPress Publications 2025-07-01
叢編:	Dermatology Reports
主題:	Psoriasis adalimumab biosimilars efficacy safety
在線閱讀:	https://www.pagepress.org/journals/dr/article/view/10315
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!